CERA

Hope in sight TM

Our research is bringing hope to people affected by vision loss and blindness

Donate Now

Help us bring hope to people with glaucoma

Help our research team develop life-changing therapies so more people with glaucoma can see clearly.

Your donation will help us advance eye research with real-life impact.

Take part in research

CERA invites people living with inherited retinal diseases (and their parents or guardians) to share their views and opinions about new potential gene therapy treatments.

Research

A world-leading multidisciplinary research project, investigating age-related macular degeneration and the factors that make some people more likely to lose their vision.

Video

In this video, learn about CERA’s research into gene therapies that could halt or even reverse vision loss in patients with conditions such as inherited retinal diseases and glaucoma.

Donate to CERA

With your support, there’s hope in sight.

Your gift will contribute to our world-leading vision research, making a real difference to people affected by vision loss and blindness.

Donate now

Take part in research

We conduct world-leading clinical trials for a range of eye conditions.

Learn more about taking part in clinical trials for conditions like age-related macular degeneration, glaucoma, diabetic retinopathy and more.

Learn more

Latest News


Research

14 April 2021

Scientists have used a new gene therapy technique to repair damage to nerve cell transport systems that cause vision loss in glaucoma and memory loss in dementia.

Stories

24 February 2021

After COVID-19 put an end to last year’s Lions Ride for Sight, veteran cyclist Jim Allen is back on his bike to raise money for vision research in 2021.

Research

22 February 2021

CERA’s new Health Services Research Unit has a mission to eliminate undetected glaucoma in the community and prevent irreversible vision loss.

Research

22 February 2021

Promising results from CERA’s clinical trial investigating the role of vitamin B3 in preventing nerve cell damage from glaucoma has sparked plans for a follow-up study.

Eye-news emails are sent to subscribers once a month

Newsletter Subscribe
Receive Appeals